Clinical Research Directory
Browse clinical research sites, groups, and studies.
4 clinical studies listed.
Filters:
Tundra lists 4 Phase 2 Study clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07817888
mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI plus bevacizumab may achieve tumor shrinkage and reduce micrometastases, offering a radiotherapy-free organ-preservation alternative for locally advanced rectal cancer. This phase II trial will enroll patients with stage II-III rectal cancer to receive six cycles of neoadjuvant mFOLFOXIRI plus bevacizumab, followed by watch-and-wait, local excision, or total mesorectal excision based on response.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-09-14
NCT07283705
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-08-20
1 state
NCT07192237
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Gender: All
Ages: 18 Years - Any
Updated: 2026-08-12
1 state
NCT07257055
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Gender: All
Ages: 18 Years - Any
Updated: 2026-05-20
1 state